Gilead Sciences Inc
MIL:1GILD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gilead Sciences Inc
MIL:1GILD
|
US |
|
Thomson Reuters Corp
NASDAQ:TRI
|
CA |
|
F
|
Fresenius Medical Care AG & Co KGaA
F:FME
|
DE |
|
E
|
Exlservice Holdings Inc
F:LHV
|
US |
|
P
|
PICC Property and Casualty Co Ltd
XMUN:PJC
|
CN |
Wall St Price Targets
1GILD Price Targets Summary
Gilead Sciences Inc
According to Wall Street analysts, the average 1-year price target for 1GILD is 141.63 EUR with a low forecast of 108.09 EUR and a high forecast of 165.79 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 1GILD's stock price target?
Price Target
141.63
EUR
According to Wall Street analysts, the average 1-year price target for 1GILD is 141.63 EUR with a low forecast of 108.09 EUR and a high forecast of 165.79 EUR.
What is the Revenue forecast for Gilead Sciences Inc?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 6%.
What is the Gross Profit forecast for Gilead Sciences Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 3 years is 8%.
What is the Operating Income forecast for Gilead Sciences Inc?
Projected CAGR
13%
Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 3 years is 13%.
What is the Pre-Tax Income forecast for Gilead Sciences Inc?
Projected CAGR
19%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 8%. The projected CAGR for the next 3 years is 19%.
What is the Net Income forecast for Gilead Sciences Inc?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 3 years is 16%.
